Nurix Therapeutics stock
NRIXNASDAQNurix Therapeutics, Inc., HealthcareISIN US67080M1036
68Score 68 out of 100, Neutral
Price and trend
37 / 100
Price history
+28% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 23% below it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 22).
The price is 44% below its 52-week high. Largest decline in 6 years: 92% (January 2021 to October 2023).
Chart figures for advanced users
- SMA 50$23.46
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$20.14
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)22
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.17
- The lowest closing price of the last twelve months.
- Resistance$27.79
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Nurix Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.7B, is number 142 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $83.98M (up 54% year on year) and a loss of $264.46M.
- For fiscal 2026, analysts expect on average revenue of $681.79M (up 711.9%) and adjusted earnings per share of $2.35.
Show more
- MEQIRI Score 68 out of 100 (Neutral): rank 166 of 702 in Healthcare, median 53.
- Our model puts fair value at $55.14, with the price 72% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 36.3% a year since 2020, Biotechnology median 19.4%.Growth 70
- High marginNet margin 42% over the last 12 months, Biotechnology median −103.7%.Profitability 99
- Below fair valuePrice 72% below the fair value of $55.14.Valuation 100
Weaknesses
- DilutionShare count up 102% since 2021.Capital allocation 54
- Analysts expect falling earningsDown 84.6% a year through 2028 (estimates from 4 analysts).
- Volatile share priceVolatility 67% a year over the last 12 months.
Its standout strengths are valuation and profitability, while technical analysis holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 69 to 68.
One-off effect in revenue
In the quarter to 31 Aug 2026, revenue of $673.06M was about 50 times the usual level. P/E, margin, growth and score for the last twelve months depend on it.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price far below its 52-week high
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $36.76 and expensive above $110.28 (uncertainty very high, based on the price swings of the past year).
Valuation metrics
From earnings times the industry P/E (21.7) alone; there are no viable cash flows for the cash-flow model.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 54% on the prior year. Revenue has grown strongly since 2018, at around 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 78%, operating −340%, net −315%. Last 12 months: net 42%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 27 Jan 2027in 75 days
- Last reported
- 12 Oct 2026EPS reported $4.73 (expected −$0.60)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 23.9% since 15 Oct 2026.
- Earnings per share
- $2.35+23.9%
- Revenue
- $681.79M+7.7%
- Earnings per share
- −$2.14−1.8%
- Revenue
- $99.61M−3.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $3.75M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- van Houte HansSale
4 Nov 2026, Chief Financial Officer
- Shares
- 4,769
- Price
- $15.63
- Value
- $74,562
- Ring ChristineSale
3 Nov 2026, Chief Legal Officer
- Shares
- 6,113
- Price
- $25.83
- Value
- $157,917
- Ring ChristineSale
2 Nov 2026, Chief Legal Officer
- Shares
- 10,602
- Price
- $25.84
- Value
- $273,987
Show 20 more
- Hansen GwennSale
2 Nov 2026, Chief Scientific Officer
- Shares
- 1,452
- Price
- $26.80
- Value
- $38,914
- van Houte HansSale
30 Oct 2026, Chief Financial Officer
- Shares
- 2,834
- Price
- $26.28
- Value
- $74,475
- Ring ChristineSale
30 Oct 2026, Chief Legal Officer
- Shares
- 3,957
- Price
- $26.28
- Value
- $103,986
- Hansen GwennSale
30 Oct 2026, Chief Scientific Officer
- Shares
- 3,957
- Price
- $26.28
- Value
- $103,986
- Hansen GwennSale
15 Oct 2026, Chief Scientific Officer
- Shares
- 1,452
- Price
- $25.00
- Value
- $36,300
- Gregory Julia PSale
14 Oct 2026, Board
- Shares
- 22,583
- Price
- $23.40
- Value
- $528,528
- Ring ChristineSale
2 Oct 2026, Chief Legal Officer
- Shares
- 5,786
- Price
- $23.19
- Value
- $134,149
- Ring ChristineSale
2 Sept 2026, Chief Legal Officer
- Shares
- 5,787
- Price
- $25.76
- Value
- $149,072
- Hansen GwennSale
1 Sept 2026, Chief Scientific Officer
- Shares
- 1,452
- Price
- $25.47
- Value
- $36,982
- Hansen GwennSale
5 Aug 2026, Chief Scientific Officer
- Shares
- 4,356
- Price
- $25.00
- Value
- $108,900
- Hansen GwennSale
4 Aug 2026, Chief Scientific Officer
- Shares
- 4,111
- Price
- $24.36
- Value
- $100,142
- van Houte HansSale
4 Aug 2026, Chief Financial Officer
- Shares
- 4,761
- Price
- $24.36
- Value
- $115,989
- Ring ChristineSale
3 Aug 2026, Chief Legal Officer
- Shares
- 16,589
- Price
- $23.05
- Value
- $382,358
- van Houte HansSale
30 Jul 2026, Chief Financial Officer
- Shares
- 2,845
- Price
- $23.38
- Value
- $66,524
- Ring ChristineSale
30 Jul 2026, Chief Legal Officer
- Shares
- 3,847
- Price
- $23.38
- Value
- $89,954
- Hansen GwennSale
30 Jul 2026, Chief Scientific Officer
- Shares
- 3,847
- Price
- $23.38
- Value
- $89,954
- Ring ChristineSale
2 Jul 2026, Chief Legal Officer
- Shares
- 11,008
- Price
- $23.56
- Value
- $259,366
- Hansen GwennSale
25 Jun 2026, Chief Scientific Officer
- Shares
- 5,394
- Price
- $20.00
- Value
- $107,880
- Ring ChristineSale
25 Jun 2026, Chief Legal Officer
- Shares
- 28,935
- Price
- $20.06
- Value
- $580,506
- Ring ChristineSale
2 Jun 2026, Chief Legal Officer
- Shares
- 8,148
- Price
- $16.60
- Value
- $135,253
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Nurix Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Sarepta TherapeuticsSRPT $1.72B39
- Kailera TherapeuticsKLRA $1.72B41
- Stoke TherapeuticsSTOK $1.71B37
- Taysha Gene TherapiesTSHA $1.71B35
- MesoblastMESO $1.7B37
- PrecigenPGEN $1.67B54
- Ultragenyx PharmaceuticalRARE $1.66B38
- NanobiotixNANO.PA $1.64B38
ETFs that hold Nurix Therapeutics
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.10% | 0.35% | €1.25B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.06% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.22B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.28B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.54B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Nov 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.